Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indrayani Biotech has submitted to BSE copies of the newspaper publication of its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. The results were approved by the Board of Directors at a meeting held on December 11, 2025 and published in Trinity Mirror (English) and Makkal Kural (Tamil) on December 13, 2025. The detailed results along with the Limited Review Report have also been posted on the company's investor relations website. This filing is being made under Regulation 47 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The letter is signed by Ramya Ravi, Company Secretary and Compliance Officer.
This is a routine regulatory compliance filing and does not contain any new financial figures or business updates on its own — it simply confirms that the already-approved Q2/H1 FY26 results have been published in newspapers as required. Shareholders seeking the actual numbers should refer to the detailed results on the company's website or the stock exchange filings.